As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
15 Analysts have issued a TG Therapeutics, Inc. forecast:
15 Analysts have issued a TG Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 532 532 |
101%
101%
|
|
| Gross Profit | 454 454 |
94%
94%
|
|
| EBITDA | 103 103 |
25,180%
25,180%
|
|
| EBIT (Operating Income) EBIT | 103 103 |
20,452%
20,452%
|
|
| Net Profit | 447 447 |
3,216%
3,216%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Michael Weiss |
| Employees | 338 |
| Founded | 1993 |
| Website | www.tgtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


